News blog

Silence Therapeutics

  • BY: Andrew Hore |
  • POSTED: 06/06/2012 |

Silence Therapeutics says that it wants to raise between 4m and 5m in order to finance its development and marketing requirements until 2014.

There was 3.69m in the bank at the end of 2011. At 1.27p a share, Silence is valued at 7.36m so the fund raising will be highly dilutive.

Silence is involved in the development of RNA interference (RNAi) therapeutics to treat serious diseases. There have been positive results from the ongoing Phase I study of Atu027, its lead internal therapeutics candidate.

The study is designed to assess different doses of Atu027 for subjects with advanced solid cancer.

Download the latest AIM Journal from

© 2021 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds